<DOC>
	<DOCNO>NCT00681317</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , PK PD effect orally administer AZD6280 single repeat ascend dos .</brief_summary>
	<brief_title>AZD6280 Multiple Ascending Dose Study</brief_title>
	<detailed_description />
	<criteria>Female subject must nonchild bear potential . Clinically significant illness within 2 week study start . Enrollment another concurrent investigational study intake investigational drug within 30 day intake investigational drug within period 5 half life drug prior screen visit Blood loss excess 200 mL within 30 day Day 2 , excess 400 mL within 90 day Day 2 , excess 1200 mL within 1 year Day 2 Clinically relevant abnormality physical examination , vital sign , ECG , clinical chemistry , hematology urinalysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>